Why this became a focus of concern
In 2023, the European Medicines Agency received reports of suicidal thoughts and self-injury associated with liraglutide and semaglutide, prompting a formal safety review. According to PubMed, a subsequent analysis of the FDA's Adverse Event Reporting System (FAERS) database found disproportionate reporting of suicidal ideation and "depression/suicidal" reports specifically for semaglutide and liraglutide compared with other diabetes medications — but critically, no disproportionate reporting of actual suicidal behavior, suicide attempts, or completed suicide for any FDA-approved GLP-1 medication (McIntyre et al., Expert Opinion on Drug Safety, 2023, DOI (external link)). The authors explicitly concluded that, using standard criteria for evaluating causality, no causal link between GLP-1 medications and suicidality was established by this data.
How to interpret this
Adverse event reporting databases like FAERS capture reports, not confirmed causation — they're a signal-detection tool, not proof of a drug effect, and are subject to reporting bias (a public safety concern can itself increase reporting rates, for example). The distinction the researchers drew — increased ideation and depression reports without increased suicidal behavior or completed suicide — is an important nuance rather than a dismissal of the concern entirely.
Where anhedonia fits in
Separate from the suicidality-specific research, our glossary entry on anhedonia covers a related but distinct concern: some patients report a general blunting of pleasure, including but not limited to food, potentially connected to GLP-1 medications' known effects on brain dopamine and reward pathways (see our guide on suppression, satiation, and satiety for the appetite-specific mechanism). This is a newer, less thoroughly studied area than the suicidality question, and remains something researchers are actively working to characterize.
What's worth taking seriously regardless
Even without established causation, persistent low mood, loss of interest in previously enjoyable activities, or any thoughts of self-harm are always worth addressing directly and promptly with a healthcare provider — mental health changes don't need a confirmed drug-causation link to warrant care and attention. If you ever have thoughts of self-harm, treat that as an emergency requiring immediate help, regardless of what's causing it.
How to raise this with your care team
Mention any mood changes clearly and specifically to your prescriber, including timing relative to starting or adjusting your dose. See our discussion guide on talking to a mental health provider about body image or disordered eating history for a related conversation that may also be relevant if food-related mood changes are part of what you're noticing.
The bottom line
Current evidence does not establish a causal link between GLP-1 medications and suicidal behavior, though increased reporting of suicidal ideation and depression has been observed and taken seriously by regulators. Regardless of the underlying cause, persistent mood changes are always worth raising with a provider — and any thoughts of self-harm warrant immediate attention.